Dartsch P C, Hildenbrand S, Kimmel R, Schmahl F W
Department of Occupational and Social Medicine, University of Tübingen, Germany.
Int Arch Occup Environ Health. 1998 Sep;71 Suppl:S40-5.
In contrast to trivalent chromium (Cr(III)) compounds, hexavalent chromium ((Cr(VI)) compounds are oxidizing agents capable of directly inducing tissue damage and possessing carcinogenic, mutagenic and teratogenic potency. After oral or dermal absorption of Cr(VI), the kidney is the main target organ for chromium accumulation, which might result in acute tubular necrosis in humans. In contrast, an acute toxic effect of Cr(VI) on the liver has not yet been described. Therefore, we used two established epithelial cell lines from the kidney (Opossum kidney cells) and the liver (Hep G2 cells) to design an in vitro-assay which is able to examine acute toxic effects of chromium compounds. Cells of both cell lines were treated with various concentrations of Cr(III) and Cr(VI) ranging from 0.01 micromol/l to 1 mmol/l for 24 h. Thereafter, cell morphology, organization of the intracellular cytoskeleton, number of viable cells and mean cell volume were examined. The results show that Cr(VI), but not Cr(III), has an acute cytotoxic effect and causes a dose-dependent loss in cell viability. The effective dose that caused 50% of cell death was 5 micromol/l for kidney epithelial cells and 50 micromol/l for liver epithelial cells. This means that kidney epithelial cells are 10 times more sensitive towards Cr(VI) treatment than liver epithelial cells and this might explain the known nephrotoxicity in vivo. The loss in cell viability was accompanied by a rounding and detachment of the cells and a marked reduction of intracellular F-actin-containing stress fibers. Microtubules and intermediate-sized filaments were observed to be unaffected. Only in the case of kidney epithelial cells, a dose-dependent cell volume increase was observed after Cr(VI) treatment at concentrations up to 50 micromol/l. At higher concentrations, the cell volume decreased due to the high number of cells undergoing lysis and the appearance of cellular fragments. Various chloride channel blockers with different specificities, molecular structures and inhibitory potentials were tested for their ability to prevent Cr(VI)-induced cell damage. None of the channel blockers was able to inhibit cell damage, suggesting that the uptake of Cr(VI) through the general anion transport system of the cell membrane might be only one facet of cellular uptake and toxification. The data presented here not only confirm the different organ-specific effects of Cr(III) and Cr(VI), but also provide a basis for future experiments on the understanding of acute toxicity of Cr(VI) compounds. Moreover, the results demonstrate that the designed in vitro-assay might be a useful tool to prove whether non-toxic Cr(III) can be oxidized to Cr(VI) under specific industrial conditions (for example, in the leather or chrome industry).
与三价铬(Cr(III))化合物不同,六价铬(Cr(VI))化合物是氧化剂,能够直接诱导组织损伤,具有致癌、致突变和致畸潜能。经口或经皮吸收Cr(VI)后,肾脏是铬蓄积的主要靶器官,这可能导致人类急性肾小管坏死。相比之下,尚未有Cr(VI)对肝脏产生急性毒性作用的描述。因此,我们使用两种已建立的来自肾脏(负鼠肾细胞)和肝脏(Hep G2细胞)的上皮细胞系设计了一种体外试验,以检测铬化合物的急性毒性作用。两种细胞系的细胞均用浓度范围为0.01微摩尔/升至1毫摩尔/升的各种Cr(III)和Cr(VI)处理24小时。此后,检查细胞形态、细胞内细胞骨架的组织、活细胞数量和平均细胞体积。结果表明,Cr(VI)而非Cr(III)具有急性细胞毒性作用,并导致细胞活力呈剂量依赖性丧失。导致50%细胞死亡的有效剂量,肾脏上皮细胞为5微摩尔/升,肝脏上皮细胞为50微摩尔/升。这意味着肾脏上皮细胞对Cr(VI)处理的敏感性比肝脏上皮细胞高10倍,这可能解释了体内已知的肾毒性。细胞活力丧失伴随着细胞变圆和脱落以及细胞内含有F-肌动蛋白的应力纤维显著减少。观察到微管和中等大小的细丝未受影响。仅在肾脏上皮细胞的情况下,在浓度高达50微摩尔/升的Cr(VI)处理后观察到剂量依赖性细胞体积增加。在更高浓度下,由于大量细胞发生裂解和细胞碎片的出现,细胞体积减小。测试了具有不同特异性、分子结构和抑制潜能的各种氯离子通道阻滞剂预防Cr(VI)诱导的细胞损伤的能力。没有一种通道阻滞剂能够抑制细胞损伤,这表明通过细胞膜的一般阴离子转运系统摄取Cr(VI)可能只是细胞摄取和毒性作用的一个方面。此处呈现的数据不仅证实了Cr(III)和Cr(VI)不同的器官特异性作用,还为未来理解Cr(VI)化合物急性毒性的实验提供了基础。此外,结果表明所设计的体外试验可能是一种有用的工具,用于证明在特定工业条件下(例如皮革或铬行业)无毒的Cr(III)是否可被氧化为Cr(VI)。